Abstract
Preclinical studies have shown that phosphodiesterase inhibitors (PDE-Is) represent a potential pharmacological strategy for the treatment of brain ischemia sequelea. PDE-Is 3, 4 and 5 have been tested in several brain ischemia models. All the three PDE-Is after acute or chronic treatment decreased the degree of neurodegeneration and most of them improved functional recovery after brain injury by specific cellular and molecular mechanisms mainly involving an anti-inflammatory and/or neuroprotection action. In contrast to the large number of investigations using PDE-Is in experimental brain ischemia research, the number of clinical studies is still limited. The purpose of this review is to summarize the data currently available on the effects of PDE-Is in experimental models of cerebral ischemia.
Keywords: Animal models, brain ischemia, stroke, phosphodiesterase inhibitors.
CNS & Neurological Disorders - Drug Targets
Title:Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia
Volume: 14 Issue: 8
Author(s): Ligia Mendes Soares, Jos Prickaerts, Humberto Milani, Elaine Del Bel, Harry Wilhelm Maria Steinbusch and Rubia Maria Weffort de Oliveira
Affiliation:
Keywords: Animal models, brain ischemia, stroke, phosphodiesterase inhibitors.
Abstract: Preclinical studies have shown that phosphodiesterase inhibitors (PDE-Is) represent a potential pharmacological strategy for the treatment of brain ischemia sequelea. PDE-Is 3, 4 and 5 have been tested in several brain ischemia models. All the three PDE-Is after acute or chronic treatment decreased the degree of neurodegeneration and most of them improved functional recovery after brain injury by specific cellular and molecular mechanisms mainly involving an anti-inflammatory and/or neuroprotection action. In contrast to the large number of investigations using PDE-Is in experimental brain ischemia research, the number of clinical studies is still limited. The purpose of this review is to summarize the data currently available on the effects of PDE-Is in experimental models of cerebral ischemia.
Export Options
About this article
Cite this article as:
Soares Mendes Ligia, Prickaerts Jos, Milani Humberto, Del Bel Elaine, Steinbusch Wilhelm Maria Harry and de Oliveira Maria Weffort Rubia, Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia, CNS & Neurological Disorders - Drug Targets 2015; 14 (8) . https://dx.doi.org/10.2174/1871527314666150909114249
DOI https://dx.doi.org/10.2174/1871527314666150909114249 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Insulin Growth Factor-I Promotes Functional Recovery After a Focal Lesion in the Dentate Gyrus
CNS & Neurological Disorders - Drug Targets Colloid Update
Current Pharmaceutical Design Brain-Derived Neurotrophic Factor and Antidepressant Activity
Current Pharmaceutical Design Cerebrospinal Fluid Proteomes: From Neural Development to Neurodegenerative Diseases
Current Proteomics Proteomic Analysis of the Kidney in Rat Biliary Cirrhosis
Current Proteomics The Regulation of Neuroimmune-Endocrine Interactions: Mechanisms,Molecular Pathways Unraveled and the Pivotal Role of Cytokines – A Unsung Putative Bidirectional Interdependence between the Immune and Neuroendocrine Interfaces
Current Immunology Reviews (Discontinued) The Effect of Cognitive Remediation Therapy on Social Skills in Institutionalized Elderly Patients with Schizophrenia
Reviews on Recent Clinical Trials Cognitive Impairment in the Septic Brain
Current Neurovascular Research Pharmacophore, QSAR, and Binding Mode Studies of Substrates of Human Cytochrome P450 2D6 (CYP2D6) Using Molecular Docking and Virtual Mutations and an Application to Chinese Herbal Medicine Screening
Current Pharmaceutical Biotechnology In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson’s Disease
Current Neuropharmacology Molecular Damage in Glaucoma: from Anterior to Posterior Eye Segment. The MicroRNA Role
MicroRNA Pharmacotherapy of Borderline Personality Disorder: A Systematic Review
Current Medicinal Chemistry Therapeutic Potential of Targeting the Endocannabinoids: Implications for the Treatment of Obesity, Metabolic Syndrome, Drug Abuse and Smoking Cessation
Current Medicinal Chemistry Neuropathic Pain and Lung Delivery of Nanoparticulate Drugs: An Emerging Novel Therapeutic Strategy
CNS & Neurological Disorders - Drug Targets The Role of Glial Cells in Drug Abuse
Current Drug Abuse Reviews Increasing Bcl-2 and Neuroglubin Expression in Hypoxic Hippocampal Neurons under Hypoxia Preconditioning and in 3-n-butylphalide Treated Cells under Oxygen Glucose Deprivation/Reoxygenation
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Clinical Pharmacology of Novel Selective COX-2 Inhibitors
Current Pharmaceutical Design Surrogate Outcomes for Progression in the Initial Stages of Diabetic Retinopathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Myalgic Encephalomyelitis: Symptoms and Biomarkers
Current Neuropharmacology Protective Effects of Anesthetics on Vascular Function Related to K<sup>+</sup> Channels
Current Pharmaceutical Design